Breaking Finance News

Zacks Investment Research downgraded Novavax, Inc. (NASDAQ:NVAX) to Hold in a report released today.

Zacks Investment Research has downgraded Novavax, Inc. (NASDAQ:NVAX) to Hold in a statement released on 1/12/2017.

Boasting a price of $1.35, Novavax, Inc. (NASDAQ:NVAX) traded -5.59% lower on the day. With the last stock price close down -66.78% from the 200-day moving average, compared to the S&P 500 which has decreased -0.05% over the same time. The company has recorded a 50-day moving average of $1.33 and a two hundred day average of $4.06. Trade Volume was down over the average, with 0 shares of NVAX changing hands under the typical 8,493,350

Recent Performance Chart

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. has 52 week low of $1.16 and a 52 week high of $8.49 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 8 brokerages have issued a ratings update on the company. The average stock price target is $15.39 with 5 brokerages rating the stock a strong buy, 3 analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.